Business
First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the first patient has been dosed in the Phase 1 portion of a Phase 1/2 clinical study evaluating AVZO-1418/DB-1418, a potential best-in-class, novel EGFR/HER3 bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumors.
About this update from Duality Biotherapeutics, Inc.
[{"type":"text","content":"SHANGHAI, July 8, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the first patient has been dosed in the Phase 1 portion of a Phase 1/2 clinical study evaluating AVZO-1418/DB-1418, a potential best-in-class, novel EGFR/HER3 bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumors.","length":503,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Duality Biologics)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Duality Biologics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":123,"url":"https://media.zenfs.com/en/prnewswire.com/8aab499770cc13543bfea972151c9da2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pmkaiGi44kW_ql_ytw5NNw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/8aab499770cc13543bfea972151c9da2","width":400,"height":123}},"href":"https://mma.prnewswire.com/media/2566332/Duality_Biologics_logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"On January 7th, 2025, DualityBio and Avenzo announced that they have entered into an exclusive license agreement, pursuant to which Avenzo will develop, manufacture and commercialize AVZO-1418/DB-1418, a potential best-in-class EGFR/HER3 bispecific ADC, globally (excluding Greater China).","length":289,"tagName":"p"},{"type":"text","content":"The Phase 1/2 first-in-human, open-label clinical study is designed to assess the safety, tolerability, and preliminary clinical activity of AVZO-1418/DB-1418 as a single agent and in combination therapy in patients with advanced solid tumors.","length":243,"tagName":"p"},{"type":"text","content":"About DualityBio ","length":16,"tagName":"p"},{"type":"text","content":"Duality Biotherapeutics (HKEX:09606) is a clinical-stage biotech company dedicated to the discovery and development of next-generation ADCs to treat cancer and autoimmune diseases. DualityBio has successfully built several cutting-edge ADC technology platforms with global intellectual property rights. Leveraging a robust pipeline, DualityBio is conducting multiple global clinical trials across 17 countries and has enrolled over 2,000 pati...